Fierce Biotech1 min read
savenChroma halves headcount, calls time on trial of potential HBV ‘cure’
nChroma Bio’s workforce are facing a second round of layoffs in 12 months, with the Boston biotech halving its headcount and scrapping a trial of its lead hepatitis asset.
comments(0)
5-min edit window · permanent after that